Trial: 202103199

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)

Phase

III

Principal Investigator

Kahl, Brad

Disease Site

Non-Hodgkin’s Lymphoma

Learn more about this study at: clinicaltrials.gov